Promising therapy for relapsed patients with aggressive form of lymphoma
A unique phase 2 clinical trial, led by researchers in the Segal Cancer Centre at the JGH, has resulted in a remission of diffuse large B-cell lymphoma for patients who have relapsed and have a particularly dire prognosis.
Pioneering effort to apply novel biotechnology to cancer research
The effort to find new biomarkers for cancer has received a major boost with the recent arrival at Lady Davis Institute of Dr. Christoph Borchers and the development of the first pan-Canadian proteomics program.
Research roundup
Dr. Roderick McInnes, Director of the Lady Davis Institute at the JGH, has received the 2015 Award for Excellence in Human Genetics Education from the American Society of Human Genetics.